Advanced Oncotherapy plc (AVO.L) Research

Advanced Oncotherapy plc, alongside its affiliated entities, specializes in the development, production, and distribution of sophisticated proton-based radiotherapy systems aimed at treating cancer. A key initiative for the company involves advancing its Linac Image Guided Hadron Technology (LIGHT) system, an innovative proton therapy solution specifically engineered for oncology applications. Furthermore, the firm oversees the management of properties within the healthcare sector. Its operational reach extends across the United Kingdom, Switzerland, and the United States. Established in 1994, the company was initially incorporated as CareCapital Group plc before adopting its current name, Advanced Oncotherapy PLC, in September 2012. Its principal offices are located in London, UK.

Market snapshot

Symbol
AVO.L
Price
$1.75
Day change
-9.09%
Market cap
$9.5M
P/E ratio
-0.19x
52-week range
0.0-25.748
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Belluscura plc (BELL.L)
  • BiVictriX Therapeutics Plc (BVX.L)
  • Celadon Pharmaceuticals Plc (CEL.L)
  • Cel AI PLC (CLAI.L)
  • Induction Healthcare Group PLC (INHC.L)
  • Kanabo Group Plc (KNB.L)
  • MGC Pharmaceuticals Limited (MXC.L)
  • NetScientific plc (NSCI.L)

Open Advanced Oncotherapy plc (AVO.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.